Washington-Watch
FDA General
More in FDA General
The answer may have more to do with how we track them, experts say
Another pricey TTR stabilizer to hit shelves
Health news and commentary gathered by ľֱ staff
We must ensure AI advances in medicine in a way that's safe, fair, and beneficial for all
Marty Makary has made a name for himself challenging the medical establishment
Committee's 2-day meeting focused on evaluating and monitoring performance and risk
Yet advisors were not inclined to take back approval for bleeding reversal agent
No one is saying for certain; a final rule is in process but has yet to be issued
New antibody indicated for previously treated, unresectable or metastatic HER2-positive disease
Panel wants to reduce barriers to the only drug indicated for treatment-resistant schizophrenia
One expert believes we're returning to "every man his own doctor"
Complete responses in 21% of patients treated with single-agent revumenib
Can severe neutropenia associated with the schizophrenia drug be monitored without it?
